A pharmaceutical that has primarily focused on reproductive and maternal health is now looking to expand into other indications. Additionally, the firm is interested in AI drug development platforms. The firm is willing to partner with early to late stage companies, and will partner globally.
The firm is interested in therapeutics in the areas of reproductive and maternal health, and is interested in expanding into the area of GI, such as therapeutics treating IBD and UC, and is interested in the microbiome as well. The firm is interested in all modalities. In addition to therapeutics, the firm is also interested in AI platforms for drug discovery and biomarker identification.
The firm has no specific company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply